Partial and transient modulation of the CD3–T‐cell receptor complex, elicited by low‐dose regimens of monoclonal anti‐CD3, is sufficient to induce disease remission in non‐obese diabetic mice
Open Access
- 6 April 2010
- journal article
- Published by Wiley in Immunology
- Vol. 130 (1), 103-113
- https://doi.org/10.1111/j.1365-2567.2009.03217.x
Abstract
It has been established that a total of 250 μg of monoclonal anti-mouse CD3 F(ab′)2 fragments, administered daily (50 μg per dose), induces remission of diabetes in the non-obese diabetic (NOD) mouse model of autoimmune diabetes by preventing β cells from undergoing further autoimmune attack. We evaluated lower-dose regimens of monoclonal anti-CD3 F(ab′)2 in diabetic NOD mice for their efficacy and associated pharmacodynamic (PD) effects, including CD3–T-cell receptor (TCR) complex modulation, complete blood counts and proportions of circulating CD4+, CD8+ and CD4+ FoxP3+ T cells. Four doses of 2 μg (total dose 8 μg) induced 53% remission of diabetes, similarly to the 250 μg dose regimen, whereas four doses of 1 μg induced only 16% remission. While the 250 μg dose regimen produced nearly complete and sustained modulation of the CD3 –TCR complex, lower doses, spaced 3 days apart, which induced similar remission rates, elicited patterns of transient and partial modulation. In treated mice, the proportions of circulating CD4+ and CD8+ T cells decreased, whereas the proportions of CD4+ FoxP3+ T cells increased; these effects were transient. Mice with greater residual β-cell function, estimated using blood glucose and C-peptide levels at the initiation of treatment, were more likely to enter remission than mice with more advanced disease. Thus, lower doses of monoclonal anti-CD3 that produced only partial and transient modulation of the CD3–TCR complex induced remission rates comparable to higher doses of monoclonal anti-CD3. Accordingly, in a clinical setting, lower-dose regimens may be efficacious and may also improve the safety profile of therapy with monoclonal anti-CD3, potentially including reductions in cytokine release-related syndromes and maintenance of pathogen-specific immunosurveillance during treatment.Keywords
This publication has 25 references indexed in Scilit:
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 yearsClinical Immunology, 2009
- Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD MiceDiabetes, 2009
- Innocuous IFNγ induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 productionThe Journal of Experimental Medicine, 2008
- CD3-specific antibodies: a portal to the treatment of autoimmunityNature Reviews Immunology, 2007
- Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatmentProceedings of the National Academy of Sciences of the United States of America, 2007
- Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing TregsJCI Insight, 2006
- Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3Immunity, 2005
- CD3-specific antibody-induced active tolerance: from bench to bedsideNature Reviews Immunology, 2003
- A humanized monovalent CD3 antibody which can activate homologous complementEuropean Journal of Immunology, 1991
- Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activationEuropean Journal of Immunology, 1990